Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2023 | Percentile | Sector n |
|---|---|---|---|---|
| Adiktologiis Regionalur… | Healthcare Services | 25.2% | 86th pct | 312 |
| Endokrinologiis Erovnul… | Healthcare Services | 24.5% | 85th pct | 312 |
| Curatio | Healthcare Services | 16.0% | 66th pct | 312 |
| Med Investment | Healthcare Services | -13.8% | 11th pct | 312 |
| Reimani | Healthcare Services | -17.8% | 9th pct | 312 |
Percentile is within each company's own sector across the whole FY2023 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2023 | Endokrinologiis Erovnul… | Curatio | Med Investment | Adiktologiis Regionalur… | Reimani |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 89.2% | 96.9% | 100.0% | 100.0% | 28.8% |
| EBITDA Margin | 24.5% | 16.0% | -13.8% | 25.2% | -17.8% |
| EBITDAR | 3,495 | 2,119 | 522 | 3,037 | -1,380 |
| EBITDAR Margin | 24.6% | 16.0% | 4.4% | 26.1% | -17.8% |
| EBIT Margin | 20.8% | 12.5% | -17.8% | 24.5% | -20.1% |
| Net Profit Margin | 18.3% | 4.9% | -15.2% | 26.2% | -20.8% |
| Operating Expense % of Sales | 64.7% | 80.9% | 113.8% | 74.8% | 46.5% |
| Returns | |||||
| Return on Assets (ROA) | 21.5% | 6.1% | -22.0% | 26.8% | -25.8% |
| Return on Equity (ROE) | 26.7% | 221.4% | N/A | 38.8% | N/A |
| ROIC [EBIT / Invested Capital] | |||||
| 26.8% |
| 18.1% |
| N/A |
| 31.8% |
| -43.1% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 15.7% | 84.7% | 7.9% | 17.5% | 156.5% |
| Debt-to-Equity | 0.20x | 30.61x | -0.25x | 0.25x | -1.77x |
| Debt-to-EBITDA | 0.54x | 4.21x | N/A | 0.68x | N/A |
| Equity-to-Assets | 80.4% | 2.8% | -32.0% | 69.0% | -88.6% |
| Net Debt | 1,288 | 8,901 | 644 | 1,084 | 9,174 |
| Cash & Equivalents | 611 | 15 | 9 | 915 | 648 |
| Total Debt | 1,898 | 8,916 | 653 | 1,999 | 9,823 |
| Liquidity & working capital | |||||
| Current Ratio | 0.51x | 0.12x | 0.14x | 1.69x | 0.61x |
| Quick Ratio | 0.51x | 0.10x | 0.14x | 1.69x | 0.61x |
| Cash Ratio | 1.30x | 0.01x | 0.00x | 0.60x | 0.26x |
| Total Current Assets | 238 | 276 | 1,091 | 2,589 | 1,527 |
| Total Current Liabilities | 469 | 2,375 | 7,655 | 1,529 | 2,516 |
| Inventory | N/A | 40 | N/A | N/A | N/A |
| Trade Receivables | 238 | 145 | 747 | 16 | 491 |
| Trade Payables | 469 | 664 | 7,655 | 1,529 | 803 |
| Net Working Capital | -232 | -2,099 | -6,564 | 1,060 | -989 |
| Net Working Capital % of Revenue | -1.6% | -15.8% | -54.8% | 9.1% | -12.7% |
| Trade Working Capital | -232 | -479 | -6,907 | -1,513 | -312 |
| Trade Working Capital % of Revenue | -1.6% | -3.6% | -57.7% | -13.0% | -4.0% |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | N/A |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | 10.51x | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | 34.7 | N/A | N/A | N/A |
| Receivables Turnover | 59.76x | 91.38x | 16.01x | 734.01x | 15.83x |
| Days Sales Outstanding (DSO) | 6.1 | 4.0 | 22.8 | 0.5 | 23.1 |
| Payables Turnover | 3.26x | 0.63x | N/A | N/A | 6.89x |
| Days Payable Outstanding (DPO) | 111.9 | 580.5 | N/A | N/A | 53.0 |
| Cash Conversion Cycle | -105.8 days | -541.7 days | 22.8 days | 0.5 days | -29.9 days |
| Asset Turnover | 1.18x | 1.26x | 1.44x | 1.02x | 1.24x |
| Cash flow & dividends | |||||
| Operating Cash Flow | N/A | 1,216 | 6 | N/A | 26 |
| Free Cash Flow (OCF − Capex proxy) | N/A | 446 | 6 | N/A | -97 |
| Cash Conversion (OCF / EBITDA) | N/A | 57.4% | N/A | N/A | N/A |
| Dividends Declared | N/A | 0 | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | 0.0% | N/A | N/A | N/A |